JP2002272489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002272489A5 JP2002272489A5 JP2002061125A JP2002061125A JP2002272489A5 JP 2002272489 A5 JP2002272489 A5 JP 2002272489A5 JP 2002061125 A JP2002061125 A JP 2002061125A JP 2002061125 A JP2002061125 A JP 2002061125A JP 2002272489 A5 JP2002272489 A5 JP 2002272489A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- oligonucleotide
- ribonucleic acid
- telomerase
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 239000002773 nucleotide Substances 0.000 description 27
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 229920002477 rna polymer Polymers 0.000 description 18
- 108010057210 telomerase RNA Proteins 0.000 description 17
- 239000000523 sample Substances 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 108010017842 Telomerase Proteins 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010025076 Holoenzymes Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27210294A | 1994-07-07 | 1994-07-07 | |
| US08/272,102 | 1994-07-07 | ||
| US08/330,123 US5583016A (en) | 1994-07-07 | 1994-10-27 | Mammalian telomerase |
| US08/330,123 | 1994-10-27 | ||
| US08/472,802 | 1995-06-07 | ||
| US08/482,115 | 1995-06-07 | ||
| US08/482,115 US5776679A (en) | 1994-07-07 | 1995-06-07 | Assays for the DNA component of human telomerase |
| US08/472,802 US5958680A (en) | 1994-07-07 | 1995-06-07 | Mammalian telomerase |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8504403A Division JPH10505488A (ja) | 1994-07-07 | 1995-07-06 | 哺乳動物のテロメラーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002272489A JP2002272489A (ja) | 2002-09-24 |
| JP2002272489A5 true JP2002272489A5 (enExample) | 2006-02-16 |
| JP4068861B2 JP4068861B2 (ja) | 2008-03-26 |
Family
ID=27501040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8504403A Withdrawn JPH10505488A (ja) | 1994-07-07 | 1995-07-06 | 哺乳動物のテロメラーゼ |
| JP2002061125A Expired - Lifetime JP4068861B2 (ja) | 1994-07-07 | 2002-03-06 | 哺乳動物のテロメラーゼ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8504403A Withdrawn JPH10505488A (ja) | 1994-07-07 | 1995-07-06 | 哺乳動物のテロメラーゼ |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP0778842B1 (enExample) |
| JP (2) | JPH10505488A (enExample) |
| KR (1) | KR100789741B1 (enExample) |
| CN (1) | CN1231491C (enExample) |
| AT (1) | ATE308554T1 (enExample) |
| AU (1) | AU696702B2 (enExample) |
| BG (1) | BG63573B1 (enExample) |
| BR (1) | BR9508254A (enExample) |
| CA (1) | CA2194393C (enExample) |
| CZ (1) | CZ3497A3 (enExample) |
| DE (1) | DE69534568T2 (enExample) |
| DK (1) | DK0778842T3 (enExample) |
| ES (1) | ES2251720T3 (enExample) |
| FI (1) | FI970026L (enExample) |
| HU (1) | HUT78054A (enExample) |
| IS (1) | IS4408A (enExample) |
| NO (1) | NO970041L (enExample) |
| NZ (1) | NZ289720A (enExample) |
| PL (1) | PL181019B1 (enExample) |
| RO (1) | RO117328B1 (enExample) |
| UA (1) | UA47407C2 (enExample) |
| WO (1) | WO1996001835A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| US5972605A (en) * | 1994-07-07 | 1999-10-26 | Geron Corporation | Assays for regulators of mammalian telomerase expression |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US6545133B1 (en) | 1995-08-04 | 2003-04-08 | Geron Corporation | Methods for purifying telomerase |
| US6517834B1 (en) | 1995-08-04 | 2003-02-11 | Geron Corporation | Purified telomerase |
| US5968506A (en) * | 1995-08-04 | 1999-10-19 | Geron Corporation | Purified telomerase |
| US5858777A (en) | 1995-09-08 | 1999-01-12 | Geron Corporation | Methods and reagents for regulating telomere length and telomerase activity |
| US6582904B2 (en) | 1995-11-16 | 2003-06-24 | Michael W. Dahm | Method of quantifying tumour cells in a body fluid and a suitable test kit |
| WO1997035967A2 (en) * | 1996-03-28 | 1997-10-02 | Cold Spring Harbor Laboratory | Transgenic organisms with altered telomerase activity |
| US6015710A (en) * | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| JPH1052300A (ja) * | 1996-06-03 | 1998-02-24 | Kyowa Hakko Kogyo Co Ltd | 細胞内テロメラーゼ活性の測定法 |
| JPH1028600A (ja) * | 1996-07-17 | 1998-02-03 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ活性の測定法 |
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6610839B1 (en) | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
| FI990655A7 (fi) * | 1996-10-01 | 1999-06-01 | Geron Corp | Ihmistelomeraasin katalyyttinen alayksikkö |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6808880B2 (en) | 1996-10-01 | 2004-10-26 | Geron Corporation | Method for detecting polynucleotides encoding telomerase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| US5919656A (en) * | 1996-11-15 | 1999-07-06 | Amgen Canada Inc. | Genes encoding telomerase protein 1 |
| US5846723A (en) * | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
| AU733610B2 (en) * | 1996-12-20 | 2001-05-17 | Geron Corporation | Methods for detecting and inhibiting the RNA component of telomerase |
| WO1998037181A2 (en) * | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
| ES2208895T3 (es) * | 1997-04-04 | 2004-06-16 | Geron Corporation | Telomerasa purificada. |
| US7622549B2 (en) | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| US7413864B2 (en) | 1997-04-18 | 2008-08-19 | Geron Corporation | Treating cancer using a telomerase vaccine |
| EP0990037A2 (de) * | 1997-06-20 | 2000-04-05 | Bayer Ag | Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung |
| CA2294782A1 (en) | 1997-07-01 | 1999-01-14 | Cambia Biosystems Llc | Vertebrate telomerase genes and proteins and uses thereof |
| EP1571215A3 (en) * | 1997-07-01 | 2007-10-31 | Cambia Biosystems LLC | Vertebrate telomerase genes and proteins and uses thereof |
| US7378244B2 (en) | 1997-10-01 | 2008-05-27 | Geron Corporation | Telomerase promoters sequences for screening telomerase modulators |
| DE19757300A1 (de) * | 1997-12-22 | 1999-06-24 | Roche Diagnostics Gmbh | Nachweis von Harnblasenkarzinom in einer Urinprobe |
| GB9801902D0 (en) * | 1998-01-29 | 1998-03-25 | Cancer Res Campaign Tech | A gene promoter |
| DE19804372A1 (de) | 1998-02-04 | 1999-08-05 | Michael W Dr Dr Dahm | Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits |
| US7402307B2 (en) * | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
| US6358739B1 (en) * | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
| WO2000074667A2 (en) * | 1999-06-04 | 2000-12-14 | Au Jessie L S | Compositions active in telomere damage comprising a taxane and telomerase inhibitor |
| US6995145B1 (en) | 1999-06-04 | 2006-02-07 | Au Jessie L-S | Methods and compositions for modulating drug activity through telomere damage |
| AU767646B2 (en) | 1999-09-10 | 2003-11-20 | Geron Corporation | Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use |
| AU1309101A (en) * | 1999-11-16 | 2001-05-30 | Kyowa Hakko Kogyo Co. Ltd. | Method of searching for substance inhibiting binding between telomerase subunits |
| ZA200509846B (en) * | 2003-06-23 | 2007-04-25 | Geron Corp | Compositions and methods for increasing telomerase activity |
| JP4690324B2 (ja) | 2003-09-09 | 2011-06-01 | ジェロン・コーポレーション | テロメラーゼ阻害のための改変オリゴヌクレオチド |
| JP4635196B2 (ja) * | 2005-03-04 | 2011-02-16 | 国立大学法人広島大学 | 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法 |
| US8785409B2 (en) | 2007-01-30 | 2014-07-22 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| EP2421955A4 (en) | 2009-04-21 | 2012-10-10 | Genetic Technologies Ltd | METHODS OF OBTAINING F TAL GENETIC MATERIAL |
| WO2012165653A1 (ja) * | 2011-05-30 | 2012-12-06 | 国立大学法人豊橋技術科学大学 | 改良されたオリゴヌクレオチドおよびそのオリゴヌクレオチドを含む医薬組成物 |
| US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| ES2657988T3 (es) * | 2013-09-13 | 2018-03-07 | F. Hoffmann-La Roche Ag | Aplicación de moléculas de oligo-dT para evitar la generación de productos de PCR de alta masa molecular inducida por transportador poliA |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| KR101628890B1 (ko) * | 2015-09-03 | 2016-06-09 | 주식회사 학표벽지 | 엠보싱 벽지 제조 장치 |
| CN115678904B (zh) * | 2021-07-22 | 2025-12-09 | 刘小川 | 一种突变的人端粒酶rna基因及其在预防和治疗泛癌种中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4312686A (en) * | 1980-02-11 | 1982-01-26 | American Biltrite Inc. | Printed and embossed floor covering and method and apparatus for its manufacture |
| JPH02179729A (ja) * | 1988-12-30 | 1990-07-12 | Shinetsu Kogyo Kk | ゲートル巻きするラッピングフィルムの製造法 |
| US5489508A (en) * | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| WO1995013382A1 (en) * | 1993-11-12 | 1995-05-18 | Geron Corporation | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| EP0666313A3 (en) * | 1994-01-27 | 1996-03-06 | Univ Iowa State Res Found Inc | Telomerase as a target in cancer gene therapy. |
| US5876979A (en) * | 1994-07-07 | 1999-03-02 | Cold Spring Harbor Laboratory | RNA component of mouse, rat, Chinese hamster and bovine telomerase |
| JPH08294966A (ja) * | 1995-04-26 | 1996-11-12 | Nippon Shokubai Co Ltd | 樹脂成形品の連続成形方法 |
| JPH10119130A (ja) | 1996-10-22 | 1998-05-12 | Japan Steel Works Ltd:The | 連続発泡体の製造方法及び装置 |
| KR100815605B1 (ko) * | 2002-02-18 | 2008-03-20 | 바프렉스 주식회사 | 공압출 다층필름의 제조방법 및 장치 |
-
1995
- 1995-07-06 AT AT95925552T patent/ATE308554T1/de active
- 1995-07-06 WO PCT/US1995/008530 patent/WO1996001835A1/en not_active Ceased
- 1995-07-06 BR BR9508254A patent/BR9508254A/pt not_active IP Right Cessation
- 1995-07-06 UA UA97010079A patent/UA47407C2/uk unknown
- 1995-07-06 FI FI970026A patent/FI970026L/fi unknown
- 1995-07-06 CN CNB951949527A patent/CN1231491C/zh not_active Expired - Lifetime
- 1995-07-06 ES ES95925552T patent/ES2251720T3/es not_active Expired - Lifetime
- 1995-07-06 DK DK95925552T patent/DK0778842T3/da active
- 1995-07-06 NZ NZ289720A patent/NZ289720A/xx not_active IP Right Cessation
- 1995-07-06 HU HU9700035A patent/HUT78054A/hu unknown
- 1995-07-06 CA CA002194393A patent/CA2194393C/en not_active Expired - Lifetime
- 1995-07-06 JP JP8504403A patent/JPH10505488A/ja not_active Withdrawn
- 1995-07-06 CZ CZ9734A patent/CZ3497A3/cs unknown
- 1995-07-06 RO RO97-00016A patent/RO117328B1/ro unknown
- 1995-07-06 DE DE69534568T patent/DE69534568T2/de not_active Expired - Lifetime
- 1995-07-06 AU AU29647/95A patent/AU696702B2/en not_active Expired
- 1995-07-06 EP EP95925552A patent/EP0778842B1/en not_active Expired - Lifetime
- 1995-07-06 EP EP02080023A patent/EP1293565A3/en not_active Withdrawn
- 1995-07-06 PL PL95318169A patent/PL181019B1/pl unknown
-
1997
- 1997-01-03 IS IS4408A patent/IS4408A/is unknown
- 1997-01-04 BG BG101103A patent/BG63573B1/bg unknown
- 1997-01-06 NO NO970041A patent/NO970041L/no not_active Application Discontinuation
-
2002
- 2002-03-06 JP JP2002061125A patent/JP4068861B2/ja not_active Expired - Lifetime
-
2003
- 2003-12-11 KR KR1020030090113A patent/KR100789741B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002272489A5 (enExample) | ||
| US12338433B2 (en) | Modified nucleic acids, hybrid guide RNAS, and uses thereof | |
| CN113631708B (zh) | 编辑rna的方法和组合物 | |
| JP6690005B2 (ja) | ナノポアシーケンシングのためのポリメラーゼ−鋳型複合体 | |
| US12065667B2 (en) | Modified Cpf1 MRNA, modified guide RNA, and uses thereof | |
| JP3010738B2 (ja) | 核酸の交雑、増幅方法 | |
| Chetverin et al. | Nonhomologous RNA recombination in a cell-free system: evidence for a transesterification mechanism guided by secondary structure | |
| KR102602047B1 (ko) | Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용 | |
| JP7531514B2 (ja) | 操作されたｍＲＮＡ配列及びその使用 | |
| CN119899831A (zh) | 编码信使核糖核酸(mRNA)的稳定核酸 | |
| JP2008532477A5 (enExample) | ||
| JP2008295444A5 (enExample) | ||
| EP1353935A2 (en) | Selection of catalytic nucleic acids targeted to infectious agents | |
| US12275951B2 (en) | Engineered guide RNA and uses thereof | |
| JP2006518186A5 (enExample) | ||
| JP2018088888A (ja) | Ｓｃｎ１ａ遺伝子の発現増強法 | |
| JP2005504523A5 (enExample) | ||
| Scaggiante et al. | Effect of unmodified triple helix‐forming oligodeoxyribonucleotide targeted to human multidrug‐resistance gene mdr1 in MDR cancer cells | |
| JP2005511023A5 (enExample) | ||
| WO2025045078A1 (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| KR20180128864A (ko) | 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법 | |
| WO2025037261A1 (en) | Methods of preventing or treating liver disease | |
| KR20170020091A (ko) | shRNA 발현 카세트의 제조방법, 그 방법에 의해 제조된 shRNA 발현 카세트 및 이를 포함하는 라이브러리 | |
| CA2408847A1 (en) | Cng3b: a novel cyclic nucleotide-gated cation channel | |
| WO2007119557A1 (ja) | コイヘルペスウイルス（ｋｈｖ）の検出方法 |